Dolby Laboratories (DLB) Financials

$74.32 -0.39 (-0.52%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$74.03 -0.29 (-0.40%)

As of 07:32 AM Eastern

Annual Income Statements for Dolby Laboratories

This table shows Dolby Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/25/2015	9/30/2016	9/29/2017	9/28/2018	9/27/2019	9/25/2020	9/24/2021	9/30/2022	9/29/2023	9/27/2024
Net Income / (Loss) Attributable to Common Shareholders	181	186	206	42	255	231	310	184	201	262
Consolidated Net Income / (Loss)	183	186	207	42	256	232	318	184	202	264
Net Income / (Loss) Continuing Operations	183	186	2,130	1,896	256	232	318	184	202	264
Total Pre-Tax Income	246	236	255	196	282	240	355	215	250	312
Total Operating Income	213	232	247	184	257	219	344	207	216	258
Total Gross Profit	876	917	1,923	1,854	1,081	1,015	1,151	1,112	1,147	1,133
Total Revenue	971	1,026	2,160	2,109	1,242	1,162	1,281	1,254	1,300	1,274
Operating Revenue	971	1,026	2,160	2,109	1,242	1,162	1,281	1,254	1,300	1,274
Total Cost of Revenue	95	109	237	255	161	146	130	141	153	140
Operating Cost of Revenue	95	109	237	255	161	146	130	141	153	140
Total Operating Expenses	663	685	-247	-184	824	797	807	906	931	875
Selling, General & Admin Expense	182	169	172	197	205	220	224	275	258	270
Marketing Expense	279	295	297	310	344	336	333	359	354	334
Research & Development Expense	201	220	233	237	238	239	254	261	272	264
Restructuring Charge	-0.08	1.23	13	-0.45	37	1.82	10	11	47	6.38
Total Other Income / (Expense), net	33	4.11	8.01	13	25	21	10	8.67	34	54
Interest Expense	0.18	0.13	0.13	0.20	0.17	0.19	-3.01	-6.17	-28	-34
Other Income / (Expense), net	28	-1.45	-1.44	-5.90	0.48	8.43	7.11	2.50	6.21	20
Income Tax Expense	63	50	48	154	27	8.10	37	31	48	48
Net Income / (Loss) Attributable to Noncontrolling Interest	1.85	0.54	0.63	0.56	0.35	0.26	7.60	-0.19	0.99	2.49
Basic Earnings per Share	$1.77	$1.85	$2.03	$0.40	$2.51	$2.30	$3.07	$1.84	$2.10	$2.74
Weighted Average Basic Shares Outstanding	102.35M	100.72M	101.78M	103.38M	101.63M	100.56M	101.19M	99.99M	95.77M	95.54M
Diluted Earnings per Share	$1.75	$1.81	$2.00	$0.39	$2.44	$2.25	$2.97	$1.81	$2.05	$2.69
Weighted Average Diluted Shares Outstanding	103.86M	102.42M	103.29M	106.98M	104.57M	102.94M	104.62M	101.98M	97.73M	97.33M
Weighted Average Basic & Diluted Shares Outstanding	102.50M	100.50M	101.90M	104.40M	101.70M	100.35M	101.16M	95.96M	95.28M	95.44M
Cash Dividends to Common per Share	$0.82	$0.98	$1.14	$1.31	$1.55	$0.88	$0.88	$2.02	$2.19	$2.43

This table shows Dolby Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	7/1/2022	9/30/2022	12/30/2022	3/31/2023	6/30/2023	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024
Net Income / (Loss) Attributable to Common Shareholders	40	28	79	96	16	9.19	67	98	38	59	68
Consolidated Net Income / (Loss)	40	28	79	96	16	9.91	68	98	40	59	68
Net Income / (Loss) Continuing Operations	40	28	79	96	16	9.91	68	98	40	59	68
Total Pre-Tax Income	49	31	100	117	24	9.03	81	122	50	60	86
Total Operating Income	46	27	94	109	16	-3.49	66	109	37	46	80
Total Gross Profit	254	241	300	335	257	255	284	326	253	271	316
Total Revenue	290	278	335	376	298	291	316	365	289	305	357
Operating Revenue	290	278	335	376	298	291	316	365	289	305	357
Total Cost of Revenue	36	37	34	41	42	36	32	39	36	34	41
Operating Cost of Revenue	36	37	34	41	42	36	32	39	36	34	41
Total Operating Expenses	208	214	206	226	241	259	217	217	216	224	236
Selling, General & Admin Expense	57	57	60	62	70	67	65	67	69	69	70
Marketing Expense	87	90	82	96	86	91	79	90	78	88	94
Research & Development Expense	63	62	64	68	69	70	67	62	66	69	67
Restructuring Charge	0.98	4.58	-0.24	0.03	17	31	6.09	-2.50	4.08	-1.29	5.22
Total Other Income / (Expense), net	3.85	3.87	5.89	8.06	7.82	13	15	13	13	13	6.17
Interest & Investment Income	1.42	-	4.80	6.81	7.20	-	9.19	8.60	9.44	-	2.65
Other Income / (Expense), net	2.51	0.67	1.10	1.25	0.62	3.25	5.43	4.18	3.94	6.53	3.53
Income Tax Expense	9.80	3.22	21	21	7.35	-0.88	13	24	11	0.87	18
Net Income / (Loss) Attributable to Noncontrolling Interest	0.01	0.00	0.07	0.19	0.01	0.72	0.60	0.38	1.21	0.30	0.25
Basic Earnings per Share	$0.40	$0.29	$0.83	$1.00	$0.17	$0.10	$0.70	$1.02	$0.40	$0.62	$0.71
Weighted Average Basic Shares Outstanding	100.21M	99.99M	95.91M	95.82M	95.66M	95.77M	95.38M	95.72M	95.69M	95.54M	95.62M
Diluted Earnings per Share	$0.39	$0.29	$0.82	$0.98	$0.17	$0.08	$0.69	$1.01	$0.40	$0.59	$0.70
Weighted Average Diluted Shares Outstanding	101.47M	101.98M	97.05M	97.30M	97.46M	97.73M	97.44M	96.86M	96.96M	97.33M	97.15M
Weighted Average Basic & Diluted Shares Outstanding	97.68M	95.96M	95.82M	95.51M	95.64M	95.28M	95.58M	95.84M	95.35M	95.44M	96.38M
Cash Dividends to Common per Share	$0.50	$0.52	$0.54	$0.54	$0.54	$0.57	$0.60	$0.60	$0.60	$0.63	$0.66

This table details how cash moves in and out of Dolby Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/25/2015	9/30/2016	9/29/2017	9/28/2018	9/27/2019	9/25/2020	9/24/2021	9/30/2022	9/29/2023	9/27/2024
Net Change in Cash & Equivalents	-37	-16	115	291	-120	274	153	-605	190	-240
Net Cash From Operating Activities	309	360	378	352	328	344	448	319	367	327
Net Cash From Continuing Operating Activities	309	360	378	352	328	344	448	319	367	327
Net Income / (Loss) Continuing Operations	183	186	207	42	256	232	318	184	202	264
Consolidated Net Income / (Loss)	183	186	207	42	256	232	318	184	202	264
Depreciation Expense	69	85	84	81	85	91	96	88	83	76
Amortization Expense	9.16	3.82	2.76	2.47	0.36	22	18	17	12	8.85
Non-Cash Adjustments To Reconcile Net Income	43	70	64	79	58	140	56	122	123	90
Changes in Operating Assets and Liabilities, net	4.38	15	20	147	-72	-140	-41	-92	-52	-111
Net Cash From Investing Activities	-204	-282	-158	78	-56	134	-45	-296	54	-286
Net Cash From Continuing Investing Activities	-204	-282	-158	78	-56	134	-45	-296	54	-286
Purchase of Property, Plant & Equipment	-158	-101	-100	-73	-96	-66	-54	-48	-30	-30
Acquisitions	-131	-121	0.00	-23	-15	0.00	-4.50	-38	26	-488
Purchase of Investments	-393	-426	-290	-174	-265	-288	-67	-316	-173	-160
Sale and/or Maturity of Investments	451	366	236	360	338	491	65	118	232	392
Other Investing Activities, net	-0.79	-0.71	-5.25	-13	-17	-2.64	0.00	-12	0.00	0.00
Net Cash From Financing Activities	-139	-92	-107	-134	-385	-208	-253	-611	-237	-288
Net Cash From Continuing Financing Activities	-139	-92	-107	-134	-385	-208	-253	-611	-237	-289
Repurchase of Common Equity	-123	-114	-118	-173	-363	-197	-278	-567	-180	-199
Payment of Dividends	-47	-49	-59	-67	-79	-89	-97	-102	-104	-130
Other Financing Activities, net	31	71	70	106	57	78	122	58	47	40
Effect of Exchange Rate Changes	-3.81	-1.40	1.68	-5.78	-5.82	3.94	2.72	-17	5.12	6.64
Cash Income Taxes Paid	52	55	57	61	60	53	71	40	61	63

This table details how cash moves in and out of Dolby Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	7/1/2022	9/30/2022	12/30/2022	3/31/2023	6/30/2023	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024
Net Change in Cash & Equivalents	-42	-239	3.11	62	106	19	-109	116	-46	-201	34
Net Cash From Operating Activities	173	51	56	105	121	85	8.41	181	21	116	107
Net Cash From Continuing Operating Activities	173	51	56	105	121	85	8.41	181	21	116	107
Net Income / (Loss) Continuing Operations	40	28	79	96	16	9.91	68	98	40	59	68
Consolidated Net Income / (Loss)	40	28	79	96	16	9.91	68	98	40	59	68
Depreciation Expense	24	19	19	21	21	21	18	18	18	21	22
Amortization Expense	4.14	3.82	3.29	3.31	3.05	2.45	2.19	1.90	2.07	2.69	2.84
Non-Cash Adjustments To Reconcile Net Income	112	23	-11	-36	122	48	-6.78	49	23	24	7.84
Changes in Operating Assets and Liabilities, net	-6.96	-22	-34	20	-41	3.17	-72	14	-62	8.90	5.67
Net Cash From Investing Activities	-8.16	-41	28	24	22	-20	0.63	-18	-7.74	-261	-8.14
Net Cash From Continuing Investing Activities	-8.16	-41	28	24	22	-20	0.63	-18	-7.74	-261	-8.14
Purchase of Property, Plant & Equipment	-11	-11	-7.22	-7.52	-7.41	-8.19	-6.10	-8.92	-7.61	-7.38	-6.78
Acquisitions	0.06	-	-	-	-	-	0.00	-	-	-488	-1.36
Purchase of Investments	-47	-63	-73	-7.77	-43	-50	-36	-68	-44	-13	0.00
Sale and/or Maturity of Investments	50	33	108	39	46	38	42	59	43	247	0.00
Net Cash From Financing Activities	-198	-242	-90	-67	-37	-43	-125	-44	-58	-60	-58
Net Cash From Continuing Financing Activities	-198	-242	-90	-67	-37	-43	-125	-45	-58	-61	-58
Repurchase of Common Equity	-191	-222	-74	-52	-27	-28	-115	-26	-36	-22	-47
Payment of Dividends	-25	-24	-26	-26	-26	-26	-30	-29	-32	-39	-32
Other Financing Activities, net	19	4.25	10	10	16	11	19	10	11	-0.01	22
Effect of Exchange Rate Changes	-	-	-	-	-0.60	-3.70	6.79	-3.68	-0.86	4.38	-7.16
Cash Income Taxes Paid	6.00	10	13	15	13	21	12	27	12	12	11

This table presents Dolby Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/25/2015	9/30/2016	9/29/2017	9/28/2018	9/27/2019	9/25/2020	9/24/2021	9/30/2022	9/29/2023	9/27/2024
Total Assets	2,133	2,310	2,534	2,865	2,822	2,917	3,106	2,690	2,980	3,110
Total Current Assets	821	760	1,011	1,497	1,382	1,547	1,760	1,311	1,488	1,194
Cash & Equivalents	532	516	627	918	797	1,072	1,225	620	745	482
Restricted Cash	2.94	3.65	7.35	7.19	8.38	8.10	7.65	8.24	73	96
Accounts Receivable	102	76	74	166	189	180	233	244	262	315
Inventories, net	14	16	25	26	32	26	11	24	36	34
Prepaid Expenses	32	26	31	35	40	53	63	50	51	70
Other Current Assets	-	-	-	166	196	161	182	176	182	197
Plant, Property, & Equipment, net	403	444	485	514	537	542	534	513	482	479
Total Noncurrent Assets	909	1,107	1,037	855	903	828	811	865	1,010	1,436
Long-Term Investments	321	394	314	188	180	52	63	103	98	89
Goodwill	308	310	311	328	335	337	341	365	408	533
Intangible Assets	128	215	190	184	181	152	123	112	167	435
Noncurrent Deferred & Refundable Income Taxes	143	167	191	75	114	119	156	184	202	220
Other Noncurrent Operating Assets	9.46	21	31	80	93	168	128	102	135	160
Total Liabilities & Shareholders' Equity	2,133	2,310	2,534	2,865	2,822	2,917	3,106	2,690	2,980	3,110
Total Liabilities	317	331	390	495	509	479	501	439	608	623
Total Current Liabilities	210	213	246	285	307	267	316	278	422	418
Accounts Payable	21	18	14	22	15	13	18	14	21	17
Accrued Expenses	169	169	207	243	268	220	263	230	351	348
Current Deferred Revenue	19	24	23	-	-	-	18	19	32	32
Current Deferred & Payable Income Tax Liabilities	0.75	2.30	1.22	2.68	3.51	3.26	1.33	1.27	4.77	9.05
Other Current Liabilities	-	-	-	17	20	31	15	13	14	12
Total Noncurrent Liabilities	108	118	144	210	202	212	186	161	185	205
Noncurrent Deferred Revenue	31	35	36	-	-	-	24	23	40	35
Other Noncurrent Operating Liabilities	77	83	108	210	202	212	162	138	145	171
Total Equity & Noncontrolling Interests	1,816	1,979	2,144	2,371	2,313	2,438	2,604	2,251	2,372	2,487
Total Preferred & Common Equity	1,807	1,970	2,137	2,364	2,307	2,433	2,598	2,246	2,355	2,477
Total Common Equity	1,807	1,970	2,137	2,364	2,307	2,433	2,598	2,246	2,355	2,477
Common Stock	18	42	61	66	0.10	0.10	0.10	0.09	0.09	0.09
Retained Earnings	1,801	1,938	2,083	2,314	2,328	2,443	2,608	2,298	2,392	2,496
Accumulated Other Comprehensive Income / (Loss)	-11	-10	-7.75	-16	-21	-11	-10	-52	-37	-19
Noncontrolling Interest	8.94	8.48	7.10	6.57	5.68	5.76	6.25	4.84	17	9.73

This table presents Dolby Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	7/1/2022	12/30/2022	3/31/2023	6/30/2023	12/29/2023	3/29/2024	6/28/2024	12/27/2024
Total Assets	2,920	2,749	2,836	3,008	2,936	3,045	2,974	3,159
Total Current Assets	1,505	1,349	1,463	1,469	1,451	1,552	1,469	1,286
Cash & Equivalents	859	626	688	765	657	710	742	521
Restricted Cash	8.35	5.32	4.98	34	52	115	37	91
Accounts Receivable	236	290	283	267	293	282	286	339
Inventories, net	24	26	30	32	38	36	35	32
Prepaid Expenses	50	53	54	54	54	50	51	82
Other Current Assets	170	216	275	193	218	243	191	221
Plant, Property, & Equipment, net	518	512	508	502	479	481	478	476
Total Noncurrent Assets	897	887	866	1,037	1,005	1,011	1,027	1,397
Long-Term Investments	107	124	101	98	93	128	118	86
Goodwill	368	369	370	426	410	409	408	520
Intangible Assets	119	106	99	177	160	152	145	421
Noncurrent Deferred & Refundable Income Taxes	184	192	204	210	207	208	220	227
Other Noncurrent Operating Assets	120	95	92	125	135	114	136	142
Total Liabilities & Shareholders' Equity	2,920	2,749	2,836	3,008	2,936	3,045	2,974	3,159
Total Liabilities	460	456	480	625	573	607	526	642
Total Current Liabilities	285	290	314	423	394	443	355	442
Accounts Payable	17	17	17	15	14	20	16	12
Accrued Expenses	229	230	247	347	327	363	281	361
Current Deferred Revenue	21	22	23	37	33	38	33	37
Current Deferred & Payable Income Tax Liabilities	3.85	7.18	14	11	6.19	8.38	12	21
Other Current Liabilities	14	13	13	14	13	14	13	11
Total Noncurrent Liabilities	175	166	166	202	179	164	172	200
Noncurrent Deferred Revenue	24	23	23	42	37	36	36	32
Other Noncurrent Operating Liabilities	151	143	143	161	142	128	136	167
Total Equity & Noncontrolling Interests	2,460	2,293	2,356	2,383	2,362	2,438	2,447	2,517
Total Preferred & Common Equity	2,454	2,288	2,351	2,366	2,346	2,421	2,433	2,508
Total Common Equity	2,454	2,288	2,351	2,366	2,346	2,421	2,433	2,508
Common Stock	0.10	0.10	0.10	0.09	0.09	0.09	0.09	0.10
Retained Earnings	2,485	2,319	2,378	2,397	2,367	2,450	2,463	2,543
Accumulated Other Comprehensive Income / (Loss)	-30	-32	-27	-31	-21	-29	-30	-36
Noncontrolling Interest	5.16	4.95	5.21	16	16	17	15	9.06

This table displays calculated financial ratios and metrics derived from Dolby Laboratories' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/25/2015	9/30/2016	9/29/2017	9/28/2018	9/27/2019	9/25/2020	9/24/2021	9/30/2022	9/29/2023	9/27/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.09%	5.68%	110.61%	-2.37%	-41.13%	-6.43%	10.28%	-2.14%	3.67%	-2.00%
EBITDA Growth	-4.63%	-0.12%	4.21%	-21.46%	31.25%	-0.93%	37.01%	-32.53%	0.79%	14.59%
EBIT Growth	-11.43%	-4.59%	6.66%	-27.71%	45.02%	-11.80%	54.73%	-40.51%	6.15%	25.43%
NOPAT Growth	-23.17%	15.21%	9.53%	-80.29%	488.55%	-9.16%	46.08%	-42.84%	-1.42%	25.59%
Net Income Growth	-12.21%	1.73%	11.11%	-79.57%	503.96%	-9.35%	37.22%	-42.14%	9.65%	31.08%
EPS Growth	-12.06%	3.43%	10.50%	-80.50%	525.64%	-7.79%	32.00%	-39.06%	13.26%	31.22%
Operating Cash Flow Growth	-14.43%	16.38%	4.92%	-6.77%	-6.96%	4.94%	30.22%	-28.85%	15.23%	-10.85%
Free Cash Flow Firm Growth	-116.99%	311.83%	222.77%	-147.00%	211.74%	55.60%	85.74%	-61.44%	63.02%	-251.40%
Invested Capital Growth	29.64%	14.88%	0.41%	13.93%	11.99%	4.19%	0.81%	4.83%	-1.03%	38.16%
Revenue Q/Q Growth	0.60%	0.02%	101.45%	-1.21%	-44.52%	-2.32%	1.09%	-0.54%	0.96%	1.13%
EBITDA Q/Q Growth	2.45%	-9.22%	-2.53%	-3.69%	13.41%	2.82%	-2.16%	-6.36%	-7.95%	17.33%
EBIT Q/Q Growth	1.67%	-12.86%	-2.85%	-5.26%	17.59%	-6.80%	2.42%	-6.52%	-11.21%	23.58%
NOPAT Q/Q Growth	-10.45%	-1.31%	0.61%	-0.81%	8.97%	-7.32%	6.37%	-8.91%	-12.48%	27.40%
Net Income Q/Q Growth	0.30%	-10.91%	1.24%	0.56%	7.16%	-6.82%	5.74%	-8.22%	-8.13%	22.73%
EPS Q/Q Growth	0.00%	-10.84%	2.04%	0.00%	7.02%	-7.02%	5.69%	-6.70%	-9.29%	23.39%
Operating Cash Flow Q/Q Growth	-2.00%	-1.95%	1.16%	9.75%	6.07%	-4.93%	-0.64%	-15.51%	10.11%	10.52%
Free Cash Flow Firm Q/Q Growth	45.27%	-4.78%	11.60%	-192.03%	174.51%	-12.09%	-0.98%	-29.45%	12.85%	-360.23%
Invested Capital Q/Q Growth	-0.80%	-0.63%	-2.59%	18.35%	-4.39%	-3.82%	-2.20%	0.17%	-3.23%	27.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.23%	89.38%	89.03%	87.90%	87.04%	87.39%	89.85%	88.73%	88.26%	88.97%
EBITDA Margin	32.94%	31.13%	15.40%	12.39%	27.63%	29.25%	36.34%	25.06%	24.36%	28.48%
Operating Margin	21.97%	22.60%	11.44%	8.70%	20.71%	18.83%	26.88%	16.48%	16.60%	20.28%
EBIT Margin	24.87%	22.46%	11.37%	8.42%	20.74%	19.55%	27.43%	16.68%	17.08%	21.86%
Profit (Net Income) Margin	18.88%	18.17%	9.59%	2.01%	20.58%	19.94%	24.81%	14.67%	15.51%	20.75%
Tax Burden Percent	74.55%	79.02%	81.17%	21.54%	90.51%	96.62%	89.65%	85.42%	80.64%	84.59%
Interest Burden Percent	101.81%	102.41%	103.85%	110.57%	109.61%	105.52%	100.86%	102.95%	112.65%	112.24%
Effective Tax Rate	25.45%	20.98%	18.83%	78.46%	9.49%	3.38%	10.35%	14.58%	19.36%	15.41%
Return on Invested Capital (ROIC)	21.86%	20.76%	21.22%	3.90%	20.34%	17.13%	24.42%	13.57%	13.14%	13.93%
ROIC Less NNEP Spread (ROIC-NNEP)	19.54%	20.44%	20.64%	3.68%	18.43%	15.35%	23.70%	12.92%	10.34%	8.61%
Return on Net Nonoperating Assets (RNNOA)	-11.53%	-10.93%	-11.17%	-2.03%	-9.43%	-7.38%	-11.81%	-6.00%	-4.42%	-3.05%
Return on Equity (ROE)	10.33%	9.82%	10.05%	1.87%	10.91%	9.75%	12.61%	7.58%	8.72%	10.88%
Cash Return on Invested Capital (CROIC)	-3.96%	6.91%	20.81%	-9.12%	9.03%	13.02%	23.61%	8.85%	14.17%	-18.11%
Operating Return on Assets (OROA)	11.73%	10.37%	10.15%	6.58%	9.06%	7.92%	11.67%	7.22%	7.83%	9.14%
Return on Assets (ROA)	8.90%	8.39%	8.55%	1.57%	8.99%	8.07%	10.55%	6.35%	7.11%	8.68%
Return on Common Equity (ROCE)	10.24%	9.78%	10.01%	1.87%	10.88%	9.73%	12.58%	7.56%	8.68%	10.82%
Return on Equity Simple (ROE_SIMPLE)	10.14%	9.46%	9.69%	1.79%	11.07%	9.52%	12.23%	8.19%	8.56%	10.67%
Net Operating Profit after Tax (NOPAT)	159	183	201	40	233	211	309	176	174	219
NOPAT Margin	16.38%	17.86%	9.29%	1.87%	18.74%	18.19%	24.10%	14.08%	13.39%	17.16%
Net Nonoperating Expense Percent (NNEP)	2.32%	0.32%	0.58%	0.22%	1.91%	1.78%	0.72%	0.66%	2.80%	5.32%
Cost of Revenue to Revenue	9.77%	10.62%	10.97%	12.10%	12.96%	12.61%	10.15%	11.27%	11.74%	11.03%
SG&A Expenses to Revenue	18.77%	16.46%	7.95%	9.36%	16.54%	18.92%	17.50%	21.96%	19.89%	21.23%
R&D to Revenue	20.74%	21.41%	10.80%	11.23%	19.16%	20.58%	19.80%	20.83%	20.89%	20.70%
Operating Expenses to Revenue	68.26%	66.78%	-11.44%	-8.70%	66.34%	68.56%	62.97%	72.25%	71.66%	68.69%
Earnings before Interest and Taxes (EBIT)	241	230	246	178	258	227	351	209	222	278
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	320	319	333	261	343	340	466	314	317	363
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.60	2.52	2.52	2.84	2.61	2.55	3.46	2.75	3.17	2.91
Price to Tangible Book Value (P/TBV)	2.11	3.44	3.29	3.63	3.36	3.20	4.21	3.50	4.20	4.78
Price to Revenue (P/Rev)	2.98	4.84	2.49	3.19	4.85	5.35	7.02	4.93	5.75	5.66
Price to Earnings (P/E)	15.93	26.74	26.07	160.96	23.62	26.85	28.99	33.59	37.22	27.53
Dividend Yield	1.42%	0.98%	1.06%	0.99%	1.27%	1.42%	0.99%	1.58%	1.70%	1.59%
Earnings Yield	6.28%	3.74%	3.84%	0.62%	4.23%	3.72%	3.45%	2.98%	2.69%	3.63%
Enterprise Value to Invested Capital (EV/IC)	2.32	4.18	4.43	5.04	4.08	4.00	6.04	3.96	4.88	3.60
Enterprise Value to Revenue (EV/Rev)	1.96	3.84	1.94	2.58	3.97	4.34	5.98	4.20	4.95	5.14
Enterprise Value to EBITDA (EV/EBITDA)	5.95	12.35	12.60	20.79	14.37	14.83	16.46	16.77	20.31	18.06
Enterprise Value to EBIT (EV/EBIT)	7.88	17.12	17.07	30.60	19.13	22.18	21.81	25.19	28.97	23.53
Enterprise Value to NOPAT (EV/NOPAT)	11.97	21.52	20.90	137.48	21.18	23.84	24.83	29.85	36.96	29.98
Enterprise Value to Operating Cash Flow (EV/OCF)	6.15	10.95	11.10	15.43	15.04	14.66	17.12	16.54	17.52	20.02
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	64.69	21.32	0.00	47.71	31.35	25.68	45.77	34.26	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.59	-0.54	-0.54	-0.55	-0.51	-0.48	-0.50	-0.46	-0.43	-0.35
Leverage Ratio	1.16	1.17	1.17	1.20	1.21	1.21	1.19	1.19	1.23	1.25
Compound Leverage Factor	1.18	1.20	1.22	1.32	1.33	1.27	1.20	1.23	1.38	1.41
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.49%	0.43%	0.33%	0.28%	0.25%	0.24%	0.24%	0.21%	0.72%	0.39%
Common Equity to Total Capital	99.50%	99.57%	99.66%	99.72%	99.75%	99.76%	99.76%	99.79%	99.28%	99.61%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.82	11.23	10.97	10.73	9.46	10.14	13.28	10.84	9.61	9.07
Noncontrolling Interest Sharing Ratio	0.87%	0.46%	0.38%	0.31%	0.26%	0.24%	0.24%	0.23%	0.47%	0.55%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.92	3.57	4.12	5.25	4.50	5.79	5.58	4.72	3.52	2.86
Quick Ratio	3.68	3.35	3.86	4.43	3.60	4.86	4.74	3.79	2.72	1.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-29	61	197	-92	103	161	299	115	188	-284
Operating Cash Flow to CapEx	196.40%	357.34%	379.25%	483.70%	340.33%	518.26%	1,175.54%	664.70%	1,209.93%	1,090.59%
Free Cash Flow to Firm to Interest Expense	-157.20	487.51	1,548.78	-466.91	607.64	864.14	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	1,690.58	2,880.51	2,974.75	1,778.80	1,927.49	1,848.65	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	829.79	2,074.42	2,190.36	1,411.05	1,361.14	1,491.95	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.46	0.89	0.78	0.44	0.40	0.43	0.43	0.46	0.42
Accounts Receivable Turnover	10.34	11.57	28.91	17.59	6.99	6.29	6.21	5.27	5.14	4.41
Inventory Turnover	8.46	7.21	11.45	9.95	5.50	5.06	7.12	8.19	5.16	4.05
Fixed Asset Turnover	2.80	2.42	4.65	4.22	2.36	2.15	2.38	2.39	2.61	2.65
Accounts Payable Turnover	5.18	5.70	14.85	14.06	8.66	10.53	8.56	8.85	8.69	7.34
Days Sales Outstanding (DSO)	35.30	31.54	12.62	20.76	52.22	58.04	58.82	69.32	71.03	82.77
Days Inventory Outstanding (DIO)	43.13	50.62	31.88	36.67	66.41	72.11	51.25	44.56	70.78	90.08
Days Payable Outstanding (DPO)	70.46	64.06	24.57	25.96	42.13	34.67	42.66	41.25	41.98	49.76
Cash Conversion Cycle (CCC)	7.97	18.09	19.93	31.46	76.50	95.47	67.41	72.63	99.83	123.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	821	943	947	1,079	1,209	1,259	1,270	1,331	1,317	1,820
Invested Capital Turnover	1.33	1.16	2.29	2.08	1.09	0.94	1.01	0.96	0.98	0.81
Increase / (Decrease) in Invested Capital	188	122	3.91	132	129	51	10	61	-14	503
Enterprise Value (EV)	1,903	3,942	4,193	5,435	4,928	5,039	7,666	5,268	6,430	6,552
Market Capitalization	2,889	4,969	5,382	6,719	6,027	6,212	8,994	6,183	7,467	7,209
Book Value per Share	$17.60	$19.52	$20.94	$22.81	$22.90	$24.18	$25.62	$23.00	$24.62	$25.98
Tangible Book Value per Share	$13.36	$14.32	$16.03	$17.87	$17.78	$19.32	$21.05	$18.11	$18.60	$15.83
Total Capital	1,816	1,979	2,144	2,371	2,313	2,438	2,604	2,251	2,372	2,487
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-995	-1,035	-1,196	-1,291	-1,104	-1,179	-1,335	-920	-1,055	-667
Capital Expenditures (CapEx)	158	101	100	73	96	66	38	48	30	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-62	-95	-116	108	150	153	173	216	108	199
Debt-free Net Working Capital (DFNWC)	612	547	766	1,211	1,075	1,280	1,445	1,033	1,066	777
Net Working Capital (NWC)	612	547	766	1,211	1,075	1,280	1,445	1,033	1,066	777
Net Nonoperating Expense (NNE)	-24	-3.25	-6.50	-2.77	-23	-20	-9.07	-7.41	-28	-46
Net Nonoperating Obligations (NNO)	-995	-1,035	-1,196	-1,291	-1,104	-1,179	-1,335	-920	-1,055	-667
Total Depreciation and Amortization (D&A)	78	89	87	84	85	113	114	105	95	84
Debt-free, Cash-free Net Working Capital to Revenue	-6.41%	-9.24%	-5.39%	5.12%	12.08%	13.18%	13.50%	17.21%	8.35%	15.61%
Debt-free Net Working Capital to Revenue	63.00%	53.29%	35.44%	57.43%	86.56%	110.18%	112.76%	82.42%	81.98%	60.97%
Net Working Capital to Revenue	63.00%	53.29%	35.44%	57.43%	86.56%	110.18%	112.76%	82.42%	81.98%	60.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.77	$1.85	$1.98	$1.18	$2.51	$2.30	$3.07	$1.84	$2.10	$2.74
Adjusted Weighted Average Basic Shares Outstanding	102.35M	100.72M	101.78M	103.38M	101.63M	100.56M	101.19M	99.99M	95.77M	95.54M
Adjusted Diluted Earnings per Share	$1.75	$1.81	$1.95	$1.14	$2.44	$2.25	$2.97	$1.81	$2.05	$2.69
Adjusted Weighted Average Diluted Shares Outstanding	103.86M	102.42M	103.29M	106.98M	104.57M	102.94M	104.62M	101.98M	97.73M	97.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$2.51	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	100.85M	101.48M	102.29M	103.26M	100.20M	100.35M	101.16M	95.96M	95.28M	95.44M
Normalized Net Operating Profit after Tax (NOPAT)	159	184	211	128	266	213	305	186	212	224
Normalized NOPAT Margin	16.37%	17.95%	9.77%	6.08%	21.40%	18.34%	23.84%	14.80%	16.31%	17.58%
Pre Tax Income Margin	25.32%	23.00%	11.81%	9.31%	22.74%	20.63%	27.67%	17.17%	19.24%	24.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1,319.24	1,842.76	1,934.61	896.98	1,515.05	1,221.38	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	868.69	1,465.24	1,579.55	199.66	1,368.65	1,136.31	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	458.44	1,036.66	1,150.22	529.23	948.69	864.67	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	7.89	659.15	795.16	-168.09	802.29	779.61	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	25.45%	26.08%	28.56%	158.79%	30.73%	38.37%	30.37%	55.19%	51.41%	49.06%
Augmented Payout Ratio	92.61%	87.50%	85.38%	566.81%	172.95%	123.34%	117.87%	363.47%	140.89%	124.37%

This table displays calculated financial ratios and metrics derived from Dolby Laboratories' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	7/1/2022	9/30/2022	12/30/2022	3/31/2023	6/30/2023	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.97%	-2.39%	-4.75%	12.42%	3.03%	4.44%	-5.78%	-3.02%	-3.20%	4.90%	13.13%
EBITDA Growth	-12.26%	-29.61%	-0.77%	95.21%	-46.36%	-53.96%	-22.03%	-1.45%	50.34%	229.76%	18.42%
EBIT Growth	-17.80%	-34.43%	4.82%	160.31%	-65.57%	-100.89%	-24.73%	2.42%	146.00%	21,508.91%	16.41%
NOPAT Growth	-29.43%	-41.41%	-5.67%	145.09%	-69.88%	-115.78%	-25.95%	-1.56%	164.25%	1,291.94%	14.13%
Net Income Growth	-27.40%	-37.24%	-0.70%	162.56%	-58.58%	-64.31%	-14.94%	2.43%	141.73%	494.13%	0.72%
EPS Growth	-25.00%	-30.95%	6.49%	172.22%	-56.41%	-72.41%	-15.85%	3.06%	135.29%	637.50%	1.45%
Operating Cash Flow Growth	0.15%	-53.26%	78.13%	65.94%	-29.82%	65.69%	-85.09%	73.53%	-82.45%	36.65%	1,169.82%
Free Cash Flow Firm Growth	-90.59%	-218.68%	-11.08%	697.47%	-463.04%	126.51%	-16.00%	82.14%	-54.56%	-4,747.65%	-949.14%
Invested Capital Growth	2.36%	4.83%	2.01%	0.34%	2.45%	-1.03%	1.13%	-4.59%	4.58%	38.16%	28.11%
Revenue Q/Q Growth	-13.39%	-3.93%	20.39%	12.23%	-20.62%	-2.62%	8.61%	15.51%	-20.77%	5.54%	17.12%
EBITDA Q/Q Growth	9.55%	-33.12%	132.12%	14.79%	-69.90%	-42.60%	293.12%	45.09%	-54.08%	25.90%	41.17%
EBIT Q/Q Growth	13.29%	-42.23%	242.70%	16.06%	-85.01%	-101.49%	29,106.48%	57.93%	-64.01%	29.85%	57.73%
NOPAT Q/Q Growth	0.25%	-33.49%	207.75%	19.44%	-87.68%	-134.83%	1,544.62%	58.77%	-66.92%	57.10%	38.33%
Net Income Q/Q Growth	8.46%	-29.92%	186.21%	20.69%	-82.89%	-39.60%	582.09%	45.33%	-59.62%	48.45%	15.64%
EPS Q/Q Growth	8.33%	-25.64%	182.76%	19.51%	-82.65%	-52.94%	762.50%	46.38%	-60.40%	47.50%	18.64%
Operating Cash Flow Q/Q Growth	173.99%	-70.27%	9.91%	85.37%	15.87%	-29.81%	-90.11%	2,057.32%	-88.28%	446.32%	-8.08%
Free Cash Flow Firm Q/Q Growth	141.94%	-725.71%	227.00%	79.27%	-125.48%	145.69%	302.38%	288.75%	-121.63%	-1,273.92%	26.48%
Invested Capital Q/Q Growth	-7.12%	0.17%	5.50%	2.22%	-5.16%	-3.23%	7.80%	-3.55%	3.95%	27.84%	-0.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.58%	86.64%	89.71%	89.08%	86.09%	87.76%	89.84%	89.36%	87.65%	88.85%	88.58%
EBITDA Margin	26.17%	18.22%	35.12%	35.92%	13.62%	8.03%	29.06%	36.50%	21.16%	25.24%	30.42%
Operating Margin	15.73%	9.74%	28.09%	29.06%	5.34%	-1.20%	20.98%	29.89%	12.74%	15.21%	22.38%
EBIT Margin	16.60%	9.98%	28.42%	29.39%	5.55%	-0.09%	22.70%	31.04%	14.10%	17.35%	23.36%
Profit (Net Income) Margin	13.68%	9.98%	23.72%	25.51%	5.50%	3.41%	21.42%	26.94%	13.73%	19.31%	19.07%
Tax Burden Percent	80.16%	89.62%	79.46%	81.75%	69.05%	109.69%	83.61%	80.67%	79.05%	98.55%	79.10%
Interest Burden Percent	102.77%	111.52%	105.04%	106.16%	143.50%	-3,657.09%	112.82%	107.60%	123.18%	112.96%	103.17%
Effective Tax Rate	19.84%	10.38%	20.54%	18.25%	30.95%	-9.69%	16.39%	19.33%	20.95%	1.45%	20.90%
Return on Invested Capital (ROIC)	12.11%	8.42%	19.86%	21.20%	3.53%	-1.29%	15.91%	21.82%	9.11%	12.17%	14.37%
ROIC Less NNEP Spread (ROIC-NNEP)	11.86%	8.11%	19.43%	20.57%	3.03%	-2.69%	14.57%	20.78%	8.07%	10.64%	13.78%
Return on Net Nonoperating Assets (RNNOA)	-5.73%	-3.77%	-8.48%	-8.69%	-1.35%	1.15%	-5.73%	-8.62%	-3.42%	-3.77%	-4.63%
Return on Equity (ROE)	6.37%	4.65%	11.38%	12.51%	2.18%	-0.15%	10.18%	13.20%	5.69%	8.40%	9.74%
Cash Return on Invested Capital (CROIC)	12.42%	8.85%	10.39%	15.37%	12.36%	14.17%	9.82%	15.62%	7.84%	-18.11%	-10.65%
Operating Return on Assets (OROA)	6.91%	4.32%	12.01%	12.74%	2.41%	-0.04%	10.23%	13.40%	5.94%	7.26%	10.08%
Return on Assets (ROA)	5.70%	4.32%	10.03%	11.06%	2.39%	1.56%	9.65%	11.63%	5.78%	8.08%	8.23%
Return on Common Equity (ROCE)	6.36%	4.64%	11.36%	12.48%	2.17%	-0.15%	10.13%	13.14%	5.65%	8.35%	9.69%
Return on Equity Simple (ROE_SIMPLE)	8.16%	0.00%	8.01%	10.32%	9.28%	0.00%	8.09%	7.94%	8.85%	0.00%	10.56%
Net Operating Profit after Tax (NOPAT)	37	24	75	89	11	-3.83	55	88	29	46	63
NOPAT Margin	12.61%	8.73%	22.32%	23.76%	3.69%	-1.32%	17.54%	24.11%	10.07%	14.99%	17.70%
Net Nonoperating Expense Percent (NNEP)	0.25%	0.31%	0.43%	0.63%	0.50%	1.39%	1.33%	1.04%	1.03%	1.53%	0.60%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	2.34%	-	-	-	2.51%
Cost of Revenue to Revenue	12.42%	13.36%	10.29%	10.92%	13.91%	12.24%	10.16%	10.64%	12.35%	11.15%	11.42%
SG&A Expenses to Revenue	19.72%	20.51%	17.91%	16.48%	23.45%	22.93%	20.65%	18.31%	23.99%	22.71%	19.63%
R&D to Revenue	21.71%	22.31%	19.24%	18.08%	23.02%	24.24%	21.24%	17.14%	22.68%	22.52%	18.67%
Operating Expenses to Revenue	71.85%	76.89%	61.62%	60.02%	80.75%	88.97%	68.86%	59.47%	74.92%	73.64%	66.20%
Earnings before Interest and Taxes (EBIT)	48	28	95	110	17	-0.25	72	113	41	53	83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	76	51	118	135	41	23	92	133	61	77	109
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.82	2.75	2.89	3.41	3.32	3.17	3.46	3.28	3.11	2.91	2.99
Price to Tangible Book Value (P/TBV)	3.52	3.50	3.64	4.26	4.45	4.20	4.57	4.27	4.02	4.78	4.78
Price to Revenue (P/Rev)	5.49	4.93	5.34	6.26	6.09	5.75	6.34	6.26	6.00	5.66	5.70
Price to Earnings (P/E)	34.51	33.59	35.99	33.04	35.79	37.22	43.10	41.73	35.59	27.53	28.51
Dividend Yield	1.41%	1.58%	1.48%	1.24%	1.29%	1.70%	1.31%	1.37%	1.48%	1.59%	1.57%
Earnings Yield	2.90%	2.98%	2.78%	3.03%	2.79%	2.69%	2.32%	2.40%	2.81%	3.63%	3.51%
Enterprise Value to Invested Capital (EV/IC)	4.36	3.96	4.07	4.94	5.02	4.88	5.06	5.03	4.60	3.60	3.74
Enterprise Value to Revenue (EV/Rev)	4.60	4.20	4.62	5.55	5.31	4.95	5.61	5.43	5.20	5.14	5.17
Enterprise Value to EBITDA (EV/EBITDA)	17.27	16.77	18.26	18.71	19.89	20.31	24.73	23.87	21.19	18.06	17.91
Enterprise Value to EBIT (EV/EBIT)	25.91	25.19	26.79	25.20	27.36	28.97	36.23	34.27	29.08	23.53	23.44
Enterprise Value to NOPAT (EV/NOPAT)	29.91	29.85	33.23	31.52	34.41	36.96	46.55	45.01	38.20	29.98	30.00
Enterprise Value to Operating Cash Flow (EV/OCF)	15.37	16.54	16.66	18.43	20.52	17.52	22.53	17.41	22.13	20.02	15.98
Enterprise Value to Free Cash Flow (EV/FCFF)	35.52	45.77	39.59	32.22	41.14	34.26	51.86	31.47	60.01	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.48	-0.46	-0.44	-0.42	-0.44	-0.43	-0.39	-0.41	-0.42	-0.35	-0.34
Leverage Ratio	1.19	1.19	1.19	1.19	1.22	1.23	1.22	1.23	1.24	1.25	1.25
Compound Leverage Factor	1.22	1.33	1.25	1.26	1.76	-44.85	1.38	1.32	1.53	1.42	1.29
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.21%	0.21%	0.22%	0.22%	0.69%	0.72%	0.70%	0.69%	0.60%	0.39%	0.36%
Common Equity to Total Capital	99.79%	99.79%	99.78%	99.78%	99.31%	99.28%	99.30%	99.31%	99.40%	99.61%	99.64%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	11.20	10.62	10.89	12.25	9.51	9.36	10.57	9.96	10.70	8.83	8.96
Noncontrolling Interest Sharing Ratio	0.23%	0.23%	0.20%	0.21%	0.45%	0.47%	0.46%	0.46%	0.64%	0.55%	0.52%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.27	4.72	4.65	4.66	3.47	3.52	3.68	3.50	4.14	2.86	2.91
Quick Ratio	4.39	3.79	3.61	3.50	2.73	2.72	2.77	2.50	3.26	1.91	1.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.93	-37	47	84	-22	9.83	40	154	-33	-457	-336
Operating Cash Flow to CapEx	1,545.97%	479.08%	781.42%	1,389.45%	1,634.01%	1,038.67%	137.88%	2,034.65%	279.31%	1,574.33%	1,575.14%
Free Cash Flow to Firm to Interest Expense	70.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	2,054.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	1,921.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.43	0.42	0.43	0.43	0.46	0.45	0.43	0.42	0.42	0.43
Accounts Receivable Turnover	4.93	5.27	4.66	5.01	5.12	5.14	4.39	4.49	4.56	4.41	4.16
Inventory Turnover	7.44	8.19	7.29	6.33	5.46	5.16	4.72	4.47	4.23	4.05	4.30
Fixed Asset Turnover	2.39	2.39	2.37	2.47	2.53	2.61	2.58	2.57	2.57	2.65	2.75
Accounts Payable Turnover	9.30	8.85	7.85	10.41	9.57	8.69	9.46	8.02	8.93	7.34	11.50
Days Sales Outstanding (DSO)	74.02	69.32	78.34	72.88	71.32	71.03	83.07	81.32	80.09	82.77	87.78
Days Inventory Outstanding (DIO)	49.03	44.56	50.06	57.68	66.87	70.78	77.39	81.62	86.22	90.08	84.88
Days Payable Outstanding (DPO)	39.25	41.25	46.50	35.05	38.13	41.98	38.59	45.53	40.87	49.76	31.73
Cash Conversion Cycle (CCC)	83.81	72.63	81.90	95.51	100.05	99.83	121.87	117.41	125.45	123.10	140.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,329	1,331	1,404	1,435	1,361	1,317	1,420	1,369	1,424	1,820	1,819
Invested Capital Turnover	0.96	0.96	0.89	0.89	0.96	0.98	0.91	0.90	0.90	0.81	0.81
Increase / (Decrease) in Invested Capital	31	61	28	4.86	33	-14	16	-66	62	503	399
Enterprise Value (EV)	5,795	5,268	5,718	7,094	6,840	6,430	7,188	6,893	6,552	6,552	6,801
Market Capitalization	6,921	6,183	6,602	8,009	7,845	7,467	8,114	7,944	7,561	7,209	7,490
Book Value per Share	$24.33	$23.00	$23.84	$24.53	$24.78	$24.62	$24.60	$25.33	$25.39	$25.98	$26.28
Tangible Book Value per Share	$19.49	$18.11	$18.89	$19.64	$18.46	$18.60	$18.62	$19.46	$19.61	$15.83	$16.41
Total Capital	2,460	2,251	2,293	2,356	2,383	2,372	2,362	2,438	2,447	2,487	2,517
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,131	-920	-888	-921	-1,021	-1,055	-942	-1,068	-1,024	-667	-698
Capital Expenditures (CapEx)	11	11	7.22	7.52	7.41	8.19	6.10	8.92	7.61	7.38	6.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	195	216	295	329	123	108	208	169	208	199	232
Debt-free Net Working Capital (DFNWC)	1,219	1,033	1,059	1,149	1,046	1,066	1,057	1,109	1,114	777	844
Net Working Capital (NWC)	1,219	1,033	1,059	1,149	1,046	1,066	1,057	1,109	1,114	777	844
Net Nonoperating Expense (NNE)	-3.08	-3.46	-4.68	-6.59	-5.40	-14	-12	-10	-11	-13	-4.88
Net Nonoperating Obligations (NNO)	-1,131	-920	-888	-921	-1,021	-1,055	-942	-1,068	-1,024	-667	-698
Total Depreciation and Amortization (D&A)	28	23	22	25	24	24	20	20	20	24	25
Debt-free, Cash-free Net Working Capital to Revenue	15.48%	17.21%	23.82%	25.71%	9.55%	8.35%	16.23%	13.29%	16.53%	15.61%	17.66%
Debt-free Net Working Capital to Revenue	96.72%	82.42%	85.60%	89.83%	81.28%	81.98%	82.57%	87.38%	88.46%	60.97%	64.17%
Net Working Capital to Revenue	96.72%	82.42%	85.60%	89.83%	81.28%	81.98%	82.57%	87.38%	88.46%	60.97%	64.17%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.40	$0.29	$0.83	$1.00	$0.17	$0.10	$0.70	$1.02	$0.40	$0.62	$0.71
Adjusted Weighted Average Basic Shares Outstanding	100.21M	99.99M	95.91M	95.82M	95.66M	95.77M	95.38M	95.72M	95.69M	95.54M	95.62M
Adjusted Diluted Earnings per Share	$0.39	$0.29	$0.82	$0.98	$0.17	$0.08	$0.69	$1.01	$0.40	$0.59	$0.70
Adjusted Weighted Average Diluted Shares Outstanding	101.47M	101.98M	97.05M	97.30M	97.46M	97.73M	97.44M	96.86M	96.96M	97.33M	97.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	97.68M	95.96M	95.82M	95.51M	95.64M	95.28M	95.58M	95.84M	95.35M	95.44M	96.38M
Normalized Net Operating Profit after Tax (NOPAT)	37	28	75	89	23	19	60	86	32	44	67
Normalized NOPAT Margin	12.88%	10.21%	22.27%	23.76%	7.55%	6.53%	19.16%	23.56%	11.18%	14.57%	18.86%
Pre Tax Income Margin	17.06%	11.13%	29.85%	31.20%	7.96%	3.11%	25.61%	33.40%	17.37%	19.60%	24.10%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	572.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	434.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	439.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	301.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	49.68%	55.19%	55.05%	41.78%	46.52%	51.41%	56.45%	57.25%	54.00%	49.06%	49.98%
Augmented Payout Ratio	270.27%	363.47%	368.04%	264.18%	217.51%	140.89%	172.68%	158.96%	149.17%	124.37%	99.81%

Frequently Asked Questions About Dolby Laboratories' Financials

When does Dolby Laboratories's fiscal year end?

According to the most recent income statement we have on file, Dolby Laboratories' financial year ends in September. Their financial year 2024 ended on September 27, 2024.

How has Dolby Laboratories' net income changed over the last 9 years?

Dolby Laboratories' net income appears to be on an upward trend, with a most recent value of $264.32 million in 2024, rising from $183.24 million in 2015. The previous period was $201.64 million in 2023. Find out what analysts predict for Dolby Laboratories in the coming months.

What is Dolby Laboratories's operating income?

Dolby Laboratories's total operating income in 2024 was $258.33 million, based on the following breakdown:

Total Gross Profit: $1.13 billion
Total Operating Expenses: $874.90 million

How has Dolby Laboratories revenue changed over the last 9 years?

Over the last 9 years, Dolby Laboratories' total revenue changed from $970.64 million in 2015 to $1.27 billion in 2024, a change of 31.2%.

How much debt does Dolby Laboratories have?

Dolby Laboratories' total liabilities were at $623.04 million at the end of 2024, a 2.5% increase from 2023, and a 96.4% increase since 2015.

How much cash does Dolby Laboratories have?

In the past 9 years, Dolby Laboratories' cash and equivalents has ranged from $482.05 million in 2024 to $1.23 billion in 2021, and is currently $482.05 million as of their latest financial filing in 2024.

How has Dolby Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Dolby Laboratories' book value per share changed from 17.60 in 2015 to 25.98 in 2024, a change of 47.6%.

Related Companies

This page (NYSE:DLB) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dolby Laboratories (DLB) Financials

Frequently Asked Questions About Dolby Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dolby Laboratories (DLB) Financials

Annual Income Statements for Dolby Laboratories

Quarterly Income Statements for Dolby Laboratories

Annual Cash Flow Statements for Dolby Laboratories

Quarterly Cash Flow Statements for Dolby Laboratories

Annual Balance Sheets for Dolby Laboratories

Quarterly Balance Sheets for Dolby Laboratories

Annual Metrics and Ratios for Dolby Laboratories

Quarterly Metrics and Ratios for Dolby Laboratories

Frequently Asked Questions About Dolby Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools